Crowdonomics
All companies
Sempresto logo

Sempresto

Raising nowOperating

SemPresto, Inc.

Biotech · Weston, MA

Woman-founded
Visit website266 followers on WeFunder · as of Oct 8, 2026

Life-saving medications, on your phone

Raising nowRaising now on WeFunder

This company has an open fundraising round.

$221K raised143 investors204 days left
View the live round
Post-money valuation ⓘ
$15.1M
As of Aug 2026 · from Reg CF Offering (2026) · pre-money + amount raised, not a traded price
Total raised
$220,991
Across 1 round since 2026
Latest share price
$1.08
Reg CF · Preferred Stock · Aug 2026 offering price

Financials

FY2024–FY2025 · from SEC filings · hover any figure for its source
$0
−$562K
2024
$0
−$2.0M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2024 reviewed
FY2025 reviewed
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$561,743
-$1,996,364
Taxes paid
$0
$0
Balance sheet
Cash
$49,811
$934,698
Accounts receivable
$0
$0
Total assets
$53,984
$1,147,125
Short-term debt
$540,615
$1,130,114
Long-term debt
$75,000
$2,575,000
Total liabilities
$615,615
$3,705,114
Other
Headcount
—
2

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$14.9M
pre-money
Reg CF · Preferred · Aug 2026

Blue bars are the pre-money valuation the company stated for a priced round.

Cap table

Principal holders% as the filing states it, Aug 24, 2026

  • Edmund Pribitkin20%+of votes
  • Elizabeth Reczek20%+of votes
  • Shawn Marcell20%+of votes

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $221K / $1.2MInvestors 143Post-money $15.1M

Team

8 people
Elizabeth ReczekFounder
Co-Founder & CEO

Veteran biotech executive. 5x CEO; raised $25M. Doubled revenue at SeqLL to $1.4M in 1 year, growing pipeline to $3.5M across 60+ clients. Harvard Biochemical Sciences BA, MIT Cancer Biology PhD. Postdoc Fellowship at Brigham & Women’s/Harvard Med School.

edmund pribitkin
Co-Founder & SAB Chairman

Medical innovator. Invented Sempresto core IP. 100+ publications. Chief Physician Executive, overseeing 10,000+ practitioners across 32 hospitals at Jefferson Health. American College of Surgeons Fellow. Johns Hopkins BA, Penn Medicine MD, Wharton MBA.

Shawn Marcell
Co-Founder & Executive Chairman

4x exited founder. 36+ years in life science & tech; founded 7 companies. Exits include ReadCoor ($350M, 10XGenomics), LifeCodes ($95M), SensiGen ($23M), Metamark (undisclosed). RedPoint Bio public by reverse merger. George Washington University Economics

Greg Dale
CTO

Product architect. Holds 36 issued US patents. Commercialized 12+ life science & medical device products ($1B+ revenue). Executive roles at Canon, Qiagen, Emulate, & Sherlock Biosciences. Virginia Tech Mechanical Engineering BS.

Matthew Copeland
CFO

IPO architect. 20+ years in pharma, medtech & biotech. CFO & financial expert in private and public sectors; worked on and launched 3+ IPOs, including Ironwood Pharmaceuticals ($203M). Ohio State Molecular Genetics BS, Northeastern MBA.

Scott Hollander
COO

Commercialization expert and volunteer EMT. 4x CEO. 25+ years executive leadership in pharma & medtech. Commercialized 20+ products globally ($2B+ revenue). Managed $1.0 B businesses. Washington University Business & Health Services Management MA.

Matt Copeland
CFO
Scott Wayne Hollander
COO

Names and titles as disclosed on WeFunder, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not obligated

never closed a Reg CF raise

143 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form CAug 24, 20260002138121-26-000001
    EDGAR
Source: SEC EDGARCIK 0002138121DEShare price $1.08Last synced Aug 24, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.